Botulinum toxin: Mechanisms of action

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 1, 2005, Pages 180-185

  Dressler, Dirk ^a,d   Adib Saheri, Fereshte ^b   Reis Barbosa, Egberto ^c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Klinik Heidberg   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d NONE   (Germany)

Author keywords

Acetylcholine; Blood brain barrier; Botulinum toxin; Exocrine glands; Mechanisms of action; Muscle spindles; Retrograde axonal transport; Smooth muscles; Stretch reflex; Substance P

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; FORMALDEHYDE; GLUTAMIC ACID; SNARE PROTEIN; SUBSTANCE P;

ACETYLCHOLINE RELEASE; ANUS FISSURE; AUTONOMIC NERVOUS SYSTEM; BLOOD BRAIN BARRIER; BRUXISM; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE; CLOSTRIDIUM BOTULINUM; CONVERGENT STRABISMUS; DETRUSOR DYSSYNERGIA; DIVERGENT STRABISMUS; DOSE RESPONSE; DRUG DIFFUSION; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSTONIA; ELECTROMYOGRAPHY; ESOPHAGUS ACHALASIA; EVOKED SOMATOSENSORY RESPONSE; EXOCRINE GLAND; FACE ASYMMETRY; GASTROINTESTINAL DISEASE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; LACRIMATION; MIGRAINE; MOTOR DYSFUNCTION; MUSCLE ATROPHY; MYOFASCIAL PAIN; MYOKYMIA; MYOTATIC REFLEX; NYSTAGMUS; ORTHOPEDIC SURGERY; PAIN; PARESIS; PTOSIS; RETROGRADE NERVE FIBER TRANSPORT; REVIEW; RHINORRHEA; SPASTICITY; STERNOCLEIDOMASTOID MUSCLE; STIFF MAN SYNDROME; STRABISMUS; STUTTERING; SYNKINESIS; TENSION HEADACHE; TETANUS; TIC; TOXIN STRUCTURE; TREMOR; VAGINISM;

EID: 17444371599     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2005000100035     Document Type: Review

References (36)

1. Kerner J. Neue Beobachtungen über die in Württemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuas geräucherter Würste. Tübingen: Osiander, 1820.
2. Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkungen auf den thierischen Organismus, ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Stuttgart: Cotta, 1822.
3. Hagenah R, Benecke R, Wiegand H. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch Pharmacol 1977;299:267-272.
4. Dressler D. Botulinum toxin therapy. Stuttgart: Thieme, 2000.
5. Rizo J, Sudhof TC. Mechanics of membrane fusion. Nat Struct Biol 1998;5:839-842.
6. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin: a selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163.
7. Pai va A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-3205.
8. Dressier D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 1997;4(Suppl 2):S67-S70.
9. Dressier D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 2000;43:13-16.
10. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-462.
11. Dressier D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;73:604.
12. Ranoux D, Gury C. Author's reply. J Neurol Neurosurg Psychiatry 2002;73:604.
13. Ludlow CL, Hallett M, Sedory SE, Fujita M, Naunton RF. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In Berardelli A, Benecke R, Manfredi M, Marsden CD (eds) Motor disturbances II. New York: Academic Press, 1990:273-288.
14. Kaji R, Kohaia N, Katayama M, et al. Musde afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 1995;18:234-235.
15. Yoshida K, Kaji R, Kubori T, Kohara N, Izuka T, Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 1998; 13:699-705.
16. Resales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-496.
17. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-404.
18. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49:34-38.
19. Takamizawa K, Iwamori M, Kozaki S, et al. Y. TLC immunostaining characterization of Clostridium botulinum type A neuro toxin binding to gangliosides and free fatty acids. FEBS Lett 1986;201:229-232.
20. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology 1986;36:545-547.
21. Wiegand H, Erdmann G, Wellhoner HH. 125I-labelled botulinum Aneurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976;292:161-165.
22. Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia: changes in reciprocal inhibition between forearm muscles. Brain 1995;118:801-807.
23. Modugno N, Priori A, Berardelu A, Vacca L, Mercuri B, Manfredi M. Botulinum toxin restores presynaptic inhibition of group la afferents in patients with essential tremor. Muscle Nerve 1998;21:1701-1705.
24. Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM. Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J Neurophysiol 1994;72:2041-2044.
25. Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000;48:20-26.
26. Dressler D, Eckert J, Kukowski B, Meyer B. Somatosensory evoked potentials in writer's cramp: pathological findings reversed by botulinum toxin therapy. EEG Clin Neurophysiol 1995;94:59.
27. Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp: a PET study. Brain 1997;120:571-582.
28. Cui M, Aoki KR Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000;20:414.
29. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000; 44:106-109.
30. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000;59:1403-1406.
31. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-258.
32. Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002;365:R17.
33. McMahon H, Foran P, Dolly J. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem 1992;267:21338-21343.
34. Shone CC, Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin: long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992;207:1009-1016.
35. Morris J, Jobling P, Gibbins I. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001;281:2124-2132.
36. Cuesta M, Arcaya J, Cano G. Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. Neurochem Int 1999;35:471-478.